Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

INTRODUCTION: Of the more than one million global cases of breast cancer diagnosed each year, approximately fifteen percent are characterized as triple-negative, lacking the estrogen, progesterone, and Her2/neu receptors. Lack of effective therapies, younger age at onset, and early metastatic spread...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Tate, Chandra R, Rhodes, Lyndsay V, Segar, H Chris, Driver, Jennifer L, Pounder, F Nell, Burow, Matthew E, Collins-Burow, Bridgette M
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2012
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3446342/
https://ncbi.nlm.nih.gov/pubmed/22613095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3192
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares